Labcorp Perspectives Oncology (Episode 7): ctDNA breakthroughs in mesothelioma care

In cancer research, true breakthroughs often happen quietly, inside trials where the rarest and toughest diseases meet cutting-edge science. One of those breakthroughs is unfolding in the fight against diffuse pleural mesothelioma, a rare but devastating cancer tied to asbestos exposure. In a recent episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs, Senior Director of Medical Affairs at Labcorp, sat down with Dr. Mark Sausen, Labcorp’s Head of Technology and Innovation, to discuss a landmark phase II trial that tested perioperative immunotherapy alongside a novel circulating tumor DNA (ctDNA) approach. The study, recently published in Nature Medicine, is helping reshape how clinicians might monitor and treat this elusive disease.